BioSpace News Archive

Nephron 503B Outsourcing Facility announces complimentary overnight shipping using the UPS Next Day Air Saver® service

Rho’s Meagan Vaughn was recently honored at the Cystic Fibrosis (CF) Foundation’s annual “Brewer’s Ball Celebrating Triangle’s Finest” event.

Bionic Vision Technologies Pty Ltd (BVT) today announced medical researchers had successfully restored a sense of vision in four blind people with its bionic eye as part of a clinical trial in Melbourne.

reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)

Tiziana Life Sciences plc today announces the pricing of its underwritten initial public offering in the United States (the “Offering”) of 442,910 American Depositary Shares (“ADSs”), representing 4,429,100 new ordinary shares of nominal value £0.03 each in the capital of the Company (“Ordinary Shares”) at an initial public offering price of $9.90 per ADS, before underwriting discounts and commissions.

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, is investigating Birner Dental Management, Inc. (''BDMS’’ or the ''Company’’) (OTC: BDMS) relating to the sale of the Company to Mid-Atlantic Dental Services Holdings, LLC.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that management will present at the 30th Annual Piper Jaffray Healthcare conference that is being held at the Lotte New York Palace hotel,

QurAlis Corporation, a biotech company focused on developing precision therapeutics for ALS and other neurological diseases, today announced the raising of a seed extension, bringing the total funding to date to $5.5 million.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that Stanford University School of Medicine has been activated as the first clinical research site for the Company’s Phase 2 trial designed to evaluate levosimendan